Arlt F, Trantakis C, Seifert V, Bootz F, Strauss G, Meixensberger J
Department of Neurosurgery, University Hospital Leipzig, Germany.
Neurol Res. 2011 Dec;33(10):1032-7. doi: 10.1179/1743132811Y.0000000027.
Recurrence rate, time to progression, and facial nerve function were analysed by comparing patients with complete and near total tumor removal after suboccipital craniotomy for vestibular schwannoma surgery.
From 1996 to 2004, 118 patients with vestibular schwannoma were operated with an interdisciplinary approach. Fifty patients fulfilled the inclusion criteria and were included in the study. Progression was defined as an increase of ⩾2 mm in the largest diameter in the magnetic resonance imaging. Preoperative tumor size, facial nerve function estimated using the House-Brackmann score (HBS), time to progression, and recurrence rate were analysed and related to the extent of resection.
In 28 cases (group I), a capsular remnant was left. In 22 cases (group II), tumor removal was complete. In group I, nine patients (32·1%) showed progression. In group II, two patients (9·1%) developed a recurrent tumor, no significance (P = 0·085). In groups I and II, 53·6 and 59·6% had a good function of the facial nerve (HBS I+II), 28·6% in group I and 13·5% in group II had a moderate disturbance (HBS III+IV), and 17·9% in group I and 27·7% in group II had a poor function (HBS V+VI). There was no significant difference between median preoperative tumor size and facial nerve function within patients with HBS III and IV.
Complete tumor removal may be associated with a risk of functional loss, whereas near total tumor removal may be associated with a higher risk of progression.
通过比较枕下开颅前庭神经鞘瘤手术中肿瘤全切和近全切患者的复发率、疾病进展时间及面神经功能来进行分析。
1996年至2004年,118例前庭神经鞘瘤患者接受了多学科联合手术。50例患者符合纳入标准并被纳入研究。疾病进展定义为磁共振成像中最大直径增加≥2mm。分析术前肿瘤大小、采用House-Brackmann评分(HBS)评估的面神经功能、疾病进展时间及复发率,并将其与切除范围相关联。
28例(I组)患者残留了肿瘤包膜。22例(II组)患者实现了肿瘤全切。I组中,9例患者(32.1%)出现疾病进展。II组中,2例患者(9.1%)出现肿瘤复发,差异无统计学意义(P = 0.085)。I组和II组中,面神经功能良好(HBS I+II)的患者分别为53.6%和59.6%,I组中28.6%、II组中13.5%的患者有中度功能障碍(HBS III+IV),I组中17.9%、II组中27.7%的患者面神经功能差(HBS V+VI)。HBS III和IV级患者术前肿瘤大小中位数及面神经功能之间无显著差异。
肿瘤全切可能与功能丧失风险相关,而近全切可能与更高的疾病进展风险相关。